Verastem, Inc., is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. It is also developing a dual inhibitor of PI3K-delta and PI3K-gamma, which has completed Phase 2 study in indolent non-hodgkin lymphoma. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and mesothelioma.
* Market cap is less than Cash;
* Insiders were buying. They bought at $7 in Sep 2018 and $3 in March 2019.
* Their lead product is in early stages of sales ramp (w 3 corporate partners) and their 2nd drug is now being fast-tracked in dev’l based on early results.
Market Cap:96.7M; Shares Outstanding:74.3M; Short Interest: 18.99%; Q3 2019(9/30/19): Cash 160M. Loss 29.7M
EPS and Sales:
|Date||EPS||% last year||% last quarter|
|Date||Sales||% last year||% last quarter|
Total institutions: 103，no change
Shares hold: 22303.6k shares. no change
shares% hold: 30.00%，no change
VSTM stock is moving higher in morning trade on January 8, 2020, after the company announced a global licensing agreement with Chugai Pharmaceuticals.